AR069600A2 - Composiciones que comprenden un polipeptido aislado, o un anticuerpo aislado o fragmento que se une al antigeno del mismo, y un vehiculo, los vectores de expresion, las celulas hospedantes, los reactivos de diagnostico, los metodos para detectar chlamydia, anticuerpos anti-chlamydia y acidos nucleic - Google Patents
Composiciones que comprenden un polipeptido aislado, o un anticuerpo aislado o fragmento que se une al antigeno del mismo, y un vehiculo, los vectores de expresion, las celulas hospedantes, los reactivos de diagnostico, los metodos para detectar chlamydia, anticuerpos anti-chlamydia y acidos nucleicInfo
- Publication number
- AR069600A2 AR069600A2 ARP080105319A ARP080105319A AR069600A2 AR 069600 A2 AR069600 A2 AR 069600A2 AR P080105319 A ARP080105319 A AR P080105319A AR P080105319 A ARP080105319 A AR P080105319A AR 069600 A2 AR069600 A2 AR 069600A2
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- polypeptide
- amino acids
- acid sequence
- amino acid
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 11
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 11
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 11
- 239000000203 mixture Substances 0.000 title abstract 6
- 150000007523 nucleic acids Chemical class 0.000 title abstract 4
- 239000012634 fragment Substances 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 239000013604 expression vector Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 9
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 7
- 241000606161 Chlamydia Species 0.000 abstract 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 239000013612 plasmid Substances 0.000 abstract 2
- 231100000699 Bacterial toxin Toxicity 0.000 abstract 1
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 241000672609 Escherichia coli BL21 Species 0.000 abstract 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- 239000000688 bacterial toxin Substances 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56927—Chlamydia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/125—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Chlamydiales (O)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/295—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Chlamydiales (o)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/813—Carrier is a saccharide
- Y10S530/814—Cellulose or derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Una composicion que comprende un polipéptido aislado y un vehiculo, caracterizada porque dicho polipéptido comprende una secuencia de aminoácidos seleccionada del grupo que consiste de: (a) una secuencia de aminoácidos codificada por una secuencia de ácido nucleico la cual hibridiza en la presencia de 50% de formamida a 37°C-42°C, a una secuencia de DNA que es complementaria de la SEQ ID N°: 1, donde dicho polipéptido se puede reconocer por medio de una preparacion de anticuerpos que se une específicamente a un polipéptido que tiene la secuencia de aminoácidos SEQ ID N°: 2; (b) los aminoácidos 29-1013 de la SEQ ID N°: 15;: (c) los aminoácidos de la SEQ ID N°: 15; (d) los aminoácidos 29-1013 de la SEQ ID N°: 16; (e) los aminoácidos de la SEQ ID N°; 16; (f) los aminoácidos 29-1012 de la SEQ ID N°: 2; (g) los aminoácidos de la SEQ ID N°: 2; (h) los aminoácidos 29-553 de la SEQ ID N°: 2; (i) los aminoácidos 29-534 de la SEQ ID N°: 15; (j)) los aminoácidos 29-534 de la SEQ ID N°: 16; (k) una secuencia de aminoácidos codificada por el inserto de Chlamydia en el plásmido pAH342 de E. coli BL21, donde dicho polipéptido se puede reconocer mediante una preparacion de anticuerpos que se unen específicamente a un polipéptido que consiste de la secuencia de aminoácidos SEQ ID N°: 2; y (l) una secuencia de aminoácidos codificada por el inserto de Chlamydia en el plásmido pJJ701 de E. coli AR58, donde dicho polipéptido se puede reconocer mediante una preparacion de anticuerpos que se unen específicamente a un polipéptido que consiste de la secuencia de aminoácidos SEQ ID N°: 2. También se describen las composiciones que comprenden un anticuerpo aislado, o fragmento que se une al antígeno del mismo, y un vehiculo, los vectores de expresion, las células hospedantes, los reactivos de diagnostico, los métodos para detectar Chlamydia, ácidos nucleicos de Chlamydia y anticuerpos anti-Chlamydia, los kit de diagnostico y el uso de dichas composiciones que comprenden un polipéptido aislado y un vehículo, el vector, o la célula hospedante, para la preparacion de medicamentos. Reivindicacion 19: La composicion segun cualquiera de las reivindicaciones 1-18, caracterizada porque además comprende una molécula de enfoque combinada con o conjugada con dicho polipéptido. Reivindicacion 20: La composicion segun la reivindicacion 19, caracterizada porque la molécula de enfoque es vitamina B12, una toxina bacterial o un fragmento de la misma, un anticuerpo monoclonal, una proteína, un ácido nucleico, un carbohidrato, o una combinacion de dos o más de dichas moléculas de enfoque.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/942,596 US7459524B1 (en) | 1997-10-02 | 1997-10-02 | Chlamydia protein, sequence and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AR069600A2 true AR069600A2 (es) | 2010-02-03 |
Family
ID=25478327
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980104960A AR018013A1 (es) | 1997-10-02 | 1998-10-05 | Una proteina de alto peso molecular (hmw) aislada de especies de chlamydia y los acidos nucleicos, vectores de expresion recombinante, celulas huespedtransformadas, proteinas recombinantes, composiciones inmunogenicas y antigenicas, metodos para producir una respuesta inmune en animales, antisueros, |
ARP080105319A AR069600A2 (es) | 1997-10-02 | 2008-12-05 | Composiciones que comprenden un polipeptido aislado, o un anticuerpo aislado o fragmento que se une al antigeno del mismo, y un vehiculo, los vectores de expresion, las celulas hospedantes, los reactivos de diagnostico, los metodos para detectar chlamydia, anticuerpos anti-chlamydia y acidos nucleic |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980104960A AR018013A1 (es) | 1997-10-02 | 1998-10-05 | Una proteina de alto peso molecular (hmw) aislada de especies de chlamydia y los acidos nucleicos, vectores de expresion recombinante, celulas huespedtransformadas, proteinas recombinantes, composiciones inmunogenicas y antigenicas, metodos para producir una respuesta inmune en animales, antisueros, |
Country Status (16)
Country | Link |
---|---|
US (6) | US7459524B1 (es) |
EP (2) | EP1862472A3 (es) |
JP (1) | JP2001518489A (es) |
KR (1) | KR100586569B1 (es) |
CN (2) | CN1911960B (es) |
AR (2) | AR018013A1 (es) |
AU (1) | AU752426B2 (es) |
BR (1) | BR9813841A (es) |
CA (1) | CA2305709A1 (es) |
CO (1) | CO5050400A1 (es) |
HK (1) | HK1034187A1 (es) |
HU (1) | HUP0004639A3 (es) |
NZ (1) | NZ503763A (es) |
SA (1) | SA99191283B1 (es) |
WO (1) | WO1999017741A1 (es) |
ZA (1) | ZA989012B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6710033B1 (en) | 1996-08-14 | 2004-03-23 | Vanderbilt University | Methods and treatment of multiple sclerosis |
US5868735A (en) | 1997-03-06 | 1999-02-09 | Scimed Life Systems, Inc. | Cryoplasty device and method |
US6890526B2 (en) | 1997-05-06 | 2005-05-10 | Vanderbilt University | Methods and reagents for the treatment of multiple sclerosis |
US7459524B1 (en) * | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
EP1169465B1 (en) * | 1998-12-04 | 2006-03-01 | University Of Manitoba | Two-step immunization procedure against chlamydia infection |
US20080213264A1 (en) * | 1998-12-08 | 2008-09-04 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
US20020061848A1 (en) * | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
CA2373021A1 (en) * | 1999-05-03 | 2000-11-09 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
EP1278855B1 (en) | 2000-04-21 | 2008-03-12 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
US6919187B2 (en) * | 2000-04-21 | 2005-07-19 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
US7537772B1 (en) | 2000-10-02 | 2009-05-26 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, gene sequence and the uses thereof |
US7731980B2 (en) | 2000-10-02 | 2010-06-08 | Emergent Product Development Gaithersburg Inc. | Chlamydia PMP proteins, gene sequences and uses thereof |
GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
ES2312649T3 (es) * | 2001-12-12 | 2009-03-01 | Novartis Vaccines And Diagnostics S.R.L. | Inmunizacion frente a chlamydia trachomatis. |
US7807802B2 (en) | 2002-11-12 | 2010-10-05 | Abbott Lab | Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae |
ITTO20050905A1 (it) * | 2005-12-23 | 2007-06-24 | Univ Degli Studi Torino | Leganti sintetici capaci di legare l'ocratossina e relativi usi |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
EP2468300B1 (en) | 2006-09-26 | 2017-12-20 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
EP2086582B1 (en) | 2006-10-12 | 2012-11-14 | GlaxoSmithKline Biologicals s.a. | Vaccine comprising an oil in water emulsion adjuvant |
CN101522218B (zh) | 2006-10-12 | 2012-09-26 | 葛兰素史密丝克莱恩生物有限公司 | 包含水包油乳液佐剂的疫苗 |
TW200908994A (en) | 2007-04-20 | 2009-03-01 | Glaxosmithkline Biolog Sa | Vaccine |
EP2162460A4 (en) * | 2007-06-14 | 2012-06-06 | Emergent Product Dev Gaithersburg Inc | VACCINES AGAINST CHLAMYDIA INFECTIONS |
US20090254588A1 (en) * | 2007-06-19 | 2009-10-08 | Zhong Li | Multi-Dimensional Data Merge |
WO2010005474A1 (en) * | 2008-06-16 | 2010-01-14 | Emergent Product Development Gaithersburg Inc. | Recombinant modified vaccinia virus ankara (mva) expressing chlamydia polypeptide antigens |
EP2326344A4 (en) * | 2008-06-16 | 2013-08-07 | Prokarium Ltd | VACCINES WITH SALMONELLA VECTOR AGAINST CHLAMYDIA AND METHOD OF ADMINISTRATION |
EP2907523B1 (en) | 2009-01-29 | 2018-03-28 | British Columbia Cancer Agency Branch | Compositions comprising chlamydia antigens |
CN102481312B (zh) | 2009-06-05 | 2015-07-15 | 传染性疾病研究院 | 合成的吡喃葡萄糖脂佐剂 |
DK2544693T3 (en) | 2010-03-09 | 2017-12-04 | Biomedical Res Models Inc | Hitherto UNKNOWN ACCESS TO VACCINATION THROUGH MILKHINDER AGAINST HERPES SIMPLEX VIRUS TYPE-2 |
EA027236B1 (ru) | 2011-04-08 | 2017-07-31 | Иммьюн Дизайн Корп. | Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа |
ES2729967T3 (es) | 2012-02-07 | 2019-11-07 | Infectious Disease Res Inst | Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas |
EP3388835B1 (en) | 2012-05-16 | 2020-04-01 | Immune Design Corp. | Vaccines for hsv-2 |
AU2014203873A1 (en) | 2013-01-07 | 2015-07-30 | Biomedical Research Models, Inc. | Therapeutic vaccines for treating herpes simplex virus type 2 infections |
CN105209047B (zh) | 2013-04-18 | 2020-08-18 | 免疫设计股份有限公司 | 用于癌症治疗的gla单一疗法 |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
US11801223B2 (en) | 2013-12-31 | 2023-10-31 | Access To Advanced Health Institute | Single vial vaccine formulations |
WO2017176076A1 (en) | 2016-04-06 | 2017-10-12 | Ewha University - Industry Collaboration Foundation | A peptide with ability to penetrate cell membrane |
JP7195147B2 (ja) | 2016-05-16 | 2022-12-23 | アクセス ツー アドバンスト ヘルス インスティチュート | Peg化リポソームおよび使用方法 |
EP4112638A1 (en) | 2016-05-16 | 2023-01-04 | Access to Advanced Health Institute | Formulation containing tlr agonist and methods of use |
MX2018014399A (es) | 2016-06-01 | 2019-06-06 | Infectious Disease Res Inst | Particulas de nanoalumbre que contienen un agente de dimensionamiento. |
WO2018232257A1 (en) | 2017-06-15 | 2018-12-20 | Infectious Disease Research Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
EP3678695A1 (en) | 2017-09-08 | 2020-07-15 | Infectious Disease Research Institute | Liposomal formulations comprising saponin and methods of use |
CA3141577A1 (en) | 2019-05-25 | 2020-12-03 | Infectious Disease Research Institute | Composition and method for spray drying an adjuvant vaccine emulsion |
AU2021337493A1 (en) | 2020-09-04 | 2023-05-18 | Access To Advanced Health Institute | Co-lyophilized rna and nanostructured lipid carrier |
WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4258029A (en) | 1979-04-23 | 1981-03-24 | Connaught Laboratories Limited | Synthetic adjuvants for stimulation of antigenic responses |
US4427782A (en) * | 1981-03-03 | 1984-01-24 | Caldwell Harlan D | Isolation of principal outer membrane protein and antigen of Chlamydia trachomatis |
US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
DE3521994A1 (de) | 1985-06-20 | 1987-01-02 | Bayer Ag | N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
US4935352A (en) | 1985-10-21 | 1990-06-19 | Takeda Chemical Industries, Ltd. | Expression vector for animal cell line and use thereof |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
DK0425082T3 (da) | 1989-09-04 | 1995-07-03 | Evans Medical Ltd | Vacciner |
US5071962A (en) | 1990-05-31 | 1991-12-10 | The United State Of America As Represented By The Department Of Health And Human Services | Nucleotide, deduced amino acid sequence, isolation and purification of heat-shock chlamydial proteins |
US5965141A (en) | 1991-02-15 | 1999-10-12 | Uab Research Foundation | Epitopic regions of pneumococcal surface protein a |
US5725863A (en) * | 1991-09-06 | 1998-03-10 | The United States Of America As Represented By The Secretary Of Agriculture | Polypeptides useful in prevention of chlamydia infection |
ATE188613T1 (de) | 1992-06-25 | 2000-01-15 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
GB9214857D0 (en) | 1992-07-13 | 1992-08-26 | Medical Res Council | Human nucleic acid fragments and their use |
IL107628A0 (en) | 1992-11-18 | 1994-02-27 | Calypte Inc | Immunoassays for microorganisms associated with sexually transmitted diseases |
DE69434221T2 (de) | 1993-09-10 | 2006-01-19 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bindungsdomänen von Plasmodius Vivax und Plasmodium Falciparum Erythrozyten bindenden Proteinen |
NZ276874A (en) | 1993-11-03 | 1997-11-24 | Pfizer | Vaccine for treating chlamydia comprising a major outer membrane protein and lipopolysaccharide preparation from a chlamydia organism |
US5565352A (en) | 1993-11-24 | 1996-10-15 | Arch Development Corporation | Deubiquitinating enzyme: compositions and methods |
KR100374448B1 (ko) | 1994-02-23 | 2003-09-13 | 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 | 효소를인코우드하는디엔에이(dna),재조합디엔에이(dna)와효소,형질전환체및이들의제조방법과용도 |
US5629167A (en) * | 1994-04-19 | 1997-05-13 | Biocine S.P.A. | Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay |
US6019982A (en) | 1994-08-26 | 2000-02-01 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic oral adjuvant |
ES2194979T3 (es) | 1995-03-28 | 2003-12-01 | Hitachi Chemical Co Ltd | Antigeno de chlamydia pneumoniae, procedimiento para su obtencion, metodo para analizar anticuerpos anti-chlamydia pneumoniae utilizandolo, y reactivo para analizar anticuerpos anti-chlamydia pneumoniae. |
GB9506863D0 (en) | 1995-04-03 | 1995-05-24 | Smithkline Beecham Biolog | Vaccines |
US5807978A (en) * | 1995-06-07 | 1998-09-15 | Kokolus; William J. | Immunogenic peptides of prostate specific antigen |
JPH09184843A (ja) * | 1995-12-28 | 1997-07-15 | Meiji Milk Prod Co Ltd | クラミジア・トラコマチス感染の診断方法 |
US6464979B1 (en) | 1996-09-12 | 2002-10-15 | Aventis Pasteur Limited | Chlamydial vaccines and methods of preparation thereof |
US7459524B1 (en) | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
KR100735651B1 (ko) | 1997-11-28 | 2007-07-06 | 세로노 제네틱스 인스티튜트 에스.에이. | 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도 |
ATE440951T1 (de) | 1997-12-17 | 2009-09-15 | Serono Genetics Inst Sa | Verlängerte cdns, die für sekretierte proteine kodieren |
US6077693A (en) * | 1998-05-14 | 2000-06-20 | Incyte Pharmaceuticals, Inc. | Polynucleotide encoding a promonocyte associated protein |
US6565856B1 (en) | 1998-12-08 | 2003-05-20 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
US20020061848A1 (en) | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
IL143531A0 (en) | 1998-12-08 | 2002-04-21 | Corixa Corp | Polypeptides containing an antigenic portion of a chlamydia antigen, dna sequences encoding said polypeptides and pharmaceutical compositions and vaccines containing the same |
US7731980B2 (en) | 2000-10-02 | 2010-06-08 | Emergent Product Development Gaithersburg Inc. | Chlamydia PMP proteins, gene sequences and uses thereof |
GB0103169D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
EP2162460A4 (en) | 2007-06-14 | 2012-06-06 | Emergent Product Dev Gaithersburg Inc | VACCINES AGAINST CHLAMYDIA INFECTIONS |
JP4743455B2 (ja) | 2009-05-26 | 2011-08-10 | トヨタ自動車株式会社 | 燃料電池システム |
-
1997
- 1997-10-02 US US08/942,596 patent/US7459524B1/en not_active Expired - Fee Related
-
1998
- 1998-10-01 EP EP07015945A patent/EP1862472A3/en not_active Withdrawn
- 1998-10-01 CN CN2006100887769A patent/CN1911960B/zh not_active Expired - Fee Related
- 1998-10-01 NZ NZ503763A patent/NZ503763A/xx not_active IP Right Cessation
- 1998-10-01 WO PCT/US1998/020737 patent/WO1999017741A1/en active IP Right Grant
- 1998-10-01 CA CA002305709A patent/CA2305709A1/en not_active Abandoned
- 1998-10-01 EP EP98949723A patent/EP1019028A4/en not_active Withdrawn
- 1998-10-01 JP JP2000514618A patent/JP2001518489A/ja active Pending
- 1998-10-01 AU AU95988/98A patent/AU752426B2/en not_active Ceased
- 1998-10-01 BR BR9813841-3A patent/BR9813841A/pt active Search and Examination
- 1998-10-01 CN CNB988118173A patent/CN1268637C/zh not_active Expired - Fee Related
- 1998-10-01 KR KR1020007003596A patent/KR100586569B1/ko not_active IP Right Cessation
- 1998-10-01 HU HU0004639A patent/HUP0004639A3/hu unknown
- 1998-10-02 ZA ZA989012A patent/ZA989012B/xx unknown
- 1998-10-02 CO CO98057476A patent/CO5050400A1/es unknown
- 1998-10-05 AR ARP980104960A patent/AR018013A1/es unknown
-
1999
- 1999-04-12 SA SA99191283A patent/SA99191283B1/ar unknown
-
2000
- 2000-04-03 US US09/542,520 patent/US6887843B1/en not_active Expired - Fee Related
- 2000-07-06 US US09/612,402 patent/US6642023B1/en not_active Expired - Fee Related
-
2001
- 2001-07-07 HK HK01104681A patent/HK1034187A1/xx unknown
-
2003
- 2003-11-04 US US10/701,844 patent/US7419807B2/en not_active Expired - Fee Related
-
2004
- 2004-01-27 US US10/766,711 patent/US7534445B2/en not_active Expired - Fee Related
- 2004-09-01 US US10/931,779 patent/US7655246B2/en not_active Expired - Fee Related
-
2008
- 2008-12-05 AR ARP080105319A patent/AR069600A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU9598898A (en) | 1999-04-27 |
US20040137005A1 (en) | 2004-07-15 |
AR018013A1 (es) | 2001-10-31 |
CN1911960B (zh) | 2012-11-07 |
CN1283108A (zh) | 2001-02-07 |
NZ503763A (en) | 2003-01-31 |
JP2001518489A (ja) | 2001-10-16 |
BR9813841A (pt) | 2000-10-03 |
AU752426B2 (en) | 2002-09-19 |
CA2305709A1 (en) | 1999-04-15 |
CN1268637C (zh) | 2006-08-09 |
HUP0004639A3 (en) | 2004-10-28 |
SA99191283B1 (ar) | 2006-04-18 |
KR20010030902A (ko) | 2001-04-16 |
CO5050400A1 (es) | 2001-06-27 |
US7459524B1 (en) | 2008-12-02 |
US20040067524A1 (en) | 2004-04-08 |
KR100586569B1 (ko) | 2006-06-02 |
US20050048557A1 (en) | 2005-03-03 |
ZA989012B (en) | 1999-04-12 |
HUP0004639A2 (hu) | 2001-04-28 |
EP1862472A2 (en) | 2007-12-05 |
US6642023B1 (en) | 2003-11-04 |
EP1019028A1 (en) | 2000-07-19 |
EP1019028A4 (en) | 2002-11-20 |
CN1911960A (zh) | 2007-02-14 |
HK1034187A1 (en) | 2001-10-19 |
US7655246B2 (en) | 2010-02-02 |
EP1862472A3 (en) | 2008-03-19 |
US7534445B2 (en) | 2009-05-19 |
WO1999017741A1 (en) | 1999-04-15 |
US7419807B2 (en) | 2008-09-02 |
US6887843B1 (en) | 2005-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR069600A2 (es) | Composiciones que comprenden un polipeptido aislado, o un anticuerpo aislado o fragmento que se une al antigeno del mismo, y un vehiculo, los vectores de expresion, las celulas hospedantes, los reactivos de diagnostico, los metodos para detectar chlamydia, anticuerpos anti-chlamydia y acidos nucleic | |
Pfanner et al. | Mitochondrial import receptors for precursor proteins | |
ES2539593T3 (es) | Inmunoglobulinas multivalentes modificadas en la región de bucle estructural | |
US5328985A (en) | Recombinant streptavidin-protein chimeras useful for conjugation of molecules in the immune system | |
WO2003046560B1 (en) | Self-assembly molecules | |
EA199800046A1 (ru) | Полипептид, последовательность днк, вакцинная композиция (варианты), антитело или его фрагмент, вакцина, применения указанных полипептида, последовательности днк и антитела или его фрагмента | |
Chilkoti et al. | Engineered chimeric streptavidin tetramers as novel tools for bioseparations and drug delivery | |
Nemoto et al. | Fluorescence labeling of the C‐terminus of proteins with a puromycin analogue in cell‐free translation systems | |
CY1108212T1 (el) | Αντιγονα συγγενη με το α-33 και οι φαρμακολογικες τους χρησεις | |
BR0106682A (pt) | Molécula de anticorpo, variante de molécula de anticorpo, anticorpo, composto, sequência de dna, vetor de clonagem ou de expressão, vetor de expressão de e. coli, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, uso da molécula de anticorpo, vetorpdnabeng-g1, vetorptto(cdp870), e, polipeptìdeo | |
BR0306979A (pt) | Polipeptìdeo isolado, proteìna de fusão, molécula isolada de polinucleotìdeo, vetor de expressão, célula cultivada, anticorpo ou fragmento de anticorpo, e, métodos para produzir uma proteìna, para produzir um anticorpo, para estimular uma resposta imune em um mamìfero, para expandir células hematopoiéticas e progenitores de células hematopoiéticas, para detectar a presença de rna zcytor17lig e de zcytor17lig em uma amostra biológica, para matar cérlulas cancerìgenas, para inibir a proliferação induzida por zcytor17lig ou diferenciação de células hematopoiéticas e progenitoras de células hematopoiéticas, para reduzir a inflamação induzida por zcytor17lig para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero acometido por uma doença inflamatória e para detectar inflamação em um paciente | |
KR950032279A (ko) | 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna) | |
SE9201331D0 (sv) | Protein l och hybridproteiner daerav | |
EA200000144A1 (ru) | Направленный цитолиз клеток-мишеней, агенты и композиции, вызывающие цитолиз, и соединения, которые можно использовать для получения этих агентов | |
JPH07507682A (ja) | Lプロテインに由来する免疫グロブリン結合性タンパク質およびその用途 | |
JPH08501213A (ja) | カチオン性ペプチド及びその製造方法 | |
BR112022021397A2 (pt) | Anticorpo anti-cd73, polipeptídeo isolado, molécula de ácido nucleico, vetor, célula hospedeira, conjugado, proteína de fusão ou anticorpo multiespecífico, kit, composição farmacêutica, uso do anticorpo e linhagem celular de hibridoma | |
US20190117791A1 (en) | Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker | |
Bierlmeier et al. | Sortase‐Mediated Multi‐Fragment Assemblies by Ligation Site Switching | |
Kumar et al. | Optimization and efficient purification of recombinant Omp28 protein of Brucella melitensis using Triton X-100 and β-mercaptoethanol | |
Liang et al. | Thiirane linkers directed histone H2A diubiquitination suggests plasticity in 53BP1 recognition | |
Evan | A simple and rapid solid phase enzyme-linked immunoadsorbence assay for screening monoclonal antibodies to poorly soluble proteins | |
JP2022130332A (ja) | 抗SARS-CoV-2抗体 | |
Käkönen et al. | Purification and characterization of recombinant osteocalcin fusion protein expressed inEscherichia coli | |
Samoylova et al. | Phage matrix for isolation of glioma cell membrane proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |